ANTI-IDIOTYPIC ANTIBODY DISCOVERY SERVICES
With Abveris anti-idiotypic antibody discovery services, you get delivery of ideal anti-idiotypic monoclonal antibodies for PK/ADA assays using proprietary technology and industry-leading workflow.
WHAT ARE ANTI-IDIOTYPIC ANTIBODIES?
Anti-idiotypic antibodies are antibodies that bind to the antigen-binding site of another antibody or biologic. Anti-idiotypic antibodies are important downstream reagents for specific drug development assays (e.g. PK and ADA), as well as many other applications such as diagnostic assays and biomarker discovery & evaluation.
There are different ways an anti-idiotypic antibody can interact with an antibody via different regions (Figure 1). The key success factor for the development is the understanding of the intended applications and design of proper screening cascades for the selection of ideal anti-idiotypic antibodies. Abveris develops industry-leading technologies and workflows that will drastically enhance the success of anti-idiotypic antibody discovery campaigns.
Idiotope:Antigenic determinant in & near CDRs Paratope:Part of antibody that recognizes antigen Epitope:Part of antigen to which paratope binds Blocking & non-blocking anti-ids are useful for assay development. |
FEATURES OF ABVERIS ANTI-IDIOTYPE DISCOVERY
Superior Antibody Diversity
-
Abveris's platform produces a diverse panel of specific anti-idiotypic antibodies using our proprietary hyperimmune DiversimAbTM Mouse
Advanced Affinity and Specificity Screenings
-
Industry-leading stringent, function-forward screening package including BOTH Octet BLI and ELISA.
-
All delivered Anti-idiotype mAbs are screened for binding in the presence of human serum by ELISA and for affinity on Octet to deliver ideal mAbs for downstream use
Rapid, Predictable Project Timelines
-
Abveris devises an industry-leading anti-idiotypic antibody discovery platform that offers both single B cell screening and integrated hybridoma workflows to significantly de-risk projects and improves the predictability of timelines vs. other discovery workflows.
Proven Expertise and 96% Success Rate
-
96% success rate based on project requirements
-
Success in different therapeutic modalities, including monoclonal antibodies, bispecifics, ADC, and cell therapy products such as CAR-T and CAT-NK
Selected Assays Supported by Abveris Anti-Idiotypic Antibodies
OUR ANTI-ID GUARANTEE:
Our anti-id guarantee promises delivery of anti-idiotypic antibodies capable of specific binding to target biologic. If we don’t find at least one, we will perform an additional screen for FREE.
ADVANTAGES OF ABVERIS ANTI-ANTIBODIES SERVICE
Rapid Discovery
2.5 months from immunization start to hc/lc sequence and validated, purified mab via b cell screening
Tailored Performance
High specificity and affinity driven by early-on advanced screenings
Superior Success Rate
A proven track record for even the most challenging projects
ANTI-IDIOTYPIC ANTIBODY PLATFORM
Learn more about our anti-idiotypic antibody platform with custom-tailored workflows:
-------------------------
ANTI-IDIOTYPIC ANTIBODY PLATFORM WITH CUSTOM-TAILORED WORKFLOWS
LEARN MORE ABOUT ABVERIS'S ANTI-IDIOTYPE ANTIBODY DISCOVERY PROGRAMS
Case Study 1:
Hybridoma-Based Anti-ID Campaign for a Bispecific Therapeutic
Case Study 2:
Ultrafast Single B Cell-Based Anti-ID Antibody Discovery
Case Study 3:
Identifying Specific mAb Binders to a CAR, Enabling Drug Quantification in Patient Serum Sample
Contact us
